397 related articles for article (PubMed ID: 30791218)
21. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
[TBL] [Abstract][Full Text] [Related]
22. Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis.
Ye P; Cai P; Xie J; Zhang J
Medicine (Baltimore); 2020 Jul; 99(28):e21171. PubMed ID: 32664155
[TBL] [Abstract][Full Text] [Related]
23. Circulating free DNA in a screening program for early colorectal cancer detection.
Perrone F; Lampis A; Bertan C; Verderio P; Ciniselli CM; Pizzamiglio S; Frattini M; Nucifora M; Molinari F; Gallino G; Gariboldi M; Meroni E; Leo E; Pierotti MA; Pilotti S
Tumori; 2014; 100(2):115-21. PubMed ID: 24852853
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
[TBL] [Abstract][Full Text] [Related]
26. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
27. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
Luo Y; Li Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
[TBL] [Abstract][Full Text] [Related]
28. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
Hou F; Sun XD; Deng ZY
Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis.
Palmieri M; Zulato E; Wahl SGF; Guibert N; Frullanti E
Front Genet; 2022; 13():1015161. PubMed ID: 36386815
[TBL] [Abstract][Full Text] [Related]
31. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
32. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
[TBL] [Abstract][Full Text] [Related]
33. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
[TBL] [Abstract][Full Text] [Related]
35. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
36. The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.
Moradi-Marjaneh R; Asgharzadeh F; Khordad E; Marjaneh MM
Curr Pharm Des; 2021; 27(7):942-952. PubMed ID: 33030125
[TBL] [Abstract][Full Text] [Related]
37. Detection of microRNA-21 expression as a potential screening biomarker for colorectal cancer: a meta-analysis.
Jiang JX; Zhang N; Liu ZM; Wang YY
Asian Pac J Cancer Prev; 2014; 15(18):7583-8. PubMed ID: 25292032
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of secreted frizzled-related protein 2 gene promoter hypermethylation in stool for colorectal cancer: A meta-analysis.
Zhou Z; Zhang H; Lei Y
J Cancer Res Ther; 2016 Oct; 12(Supplement):30-33. PubMed ID: 27721248
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
[TBL] [Abstract][Full Text] [Related]
40. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
Han JY; Choi JJ; Kim JY; Han YL; Lee GK
BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
